We know radiation. It can do a world of good. It can also cause irreparable harm.
We make radiation safer, so people can heal and thrive.
F3 brings existing radioprotective and cytoprotective science to market in new and meaningful ways.
Our biopharmaceutical platform represents exciting current and future solutions to critical health issues related to radiation exposure.
Our first application coming to market, AmiGuard CT™ , is a lower dose regimen of the FDA approved drug Amifostine—a solution that helps prevent radiation-induced genomic damage and instability (RIGDI), such as from the radiation present in CT scans. RIGDI is a precursor to carcinogenesis.
We hold a worldwide exclusive license and patents for a broad spectrum of applications and markets for Amifostine and other compounds. We have a history of proven success in biotechnologies that help people while generating value for investors and partners.